Phase 1 Lupus Trial, Recruiting NCT07331467 Sponsor: Chongqing Precision Biotech Co., Ltd Condition: Lupus
Back to Lupus

Phase 1 Lupus Trial, Recruiting

NCT07331467
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People diagnosed with Systemic Lupus Erythematosus (SLE, a type of autoimmune disease) according to specific 2019 international classification guidelines, whose disease is still moderately to severely active despite at least 3 months of high-dose steroid treatment and at least 2 other standard medications, or who are unable to tolerate standard treatments
  • People whose SLE disease activity scores 8 points or higher on a standard medical measurement scale called SLEDAI-2K
  • People whose health allows for a procedure to collect white blood cells from the blood, with no medical reasons preventing this procedure
  • Women of childbearing age whose pregnancy test result is negative, and who agree to use effective contraception for at least one year after receiving the trial treatment
  • People (or their legal guardians) who understand the purpose and process of the trial and agree in writing to take part

Who may not be able to join:

  • People with lupus affecting the brain or nervous system that has required medical intervention within the last 30 days
  • People with a history of certain serious heart conditions, including: a heart attack within the last 6 months, serious irregular heartbeats, severe heart failure (classified as NYHA Class IV), significant fluid around the heart, serious heart muscle inflammation, or unstable blood pressure requiring medication
  • People whose kidneys, liver, or lungs are not functioning well enough — specifically if kidney filtration is very low or requires dialysis, if certain liver enzyme or bilirubin levels are significantly elevated, or if blood oxygen levels are below 92% without supplemental oxygen
  • People with an active or uncontrolled infection that has required whole-body treatment within the past 3 months
  • People who have had a bone marrow or stem cell transplant within the past 3 months, or who are experiencing a significant transplant-related immune reaction within the past 2 weeks
  • People who have active Hepatitis B, Hepatitis C, HIV, or syphilis infections (confirm with trial site for specific test thresholds)
  • People with active tuberculosis at the time of screening
  • People who have received a live vaccine within the 4 weeks before screening
  • People with a positive blood pregnancy test
  • People with an active cancer diagnosis (some fully treated or resolved cancers may not apply — confirm with trial site)
  • People who have taken part in another clinical trial within the past 3 months
  • People whom the trial doctors consider unsuitable for any other medical reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13705186409

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Chongqing Precision Biotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
1 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The safety of CAR-T cell therapy in patients with refractory SLE [Safety]; The changes from baseline in SLEDAI-2K [efficacy]; The changes from baseline in PGA [efficacy]; The changes from baseline in BILAG-2004 [efficacy]; The number of patients with SRI-4 response [efficacy]; The number of patients with LLDAS [efficacy]; The number of patients with DORIS [efficacy]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov